查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990539

FASN抑制剂市场：全球市场预测（依适应症、产品类型、剂型、最终用户和通路划分），2026-2032年

FASN Inhibitor Market by Indication, Product Type, Formulation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 FASN 抑制剂市场在 2025 年的价值为 3.8687 亿美元，在 2026 年成长至 4.1809 亿美元，到 2032 年达到 6.8794 亿美元，复合年增长率为 8.57%。

主要市场统计数据
基准年 2025 3.8687亿美元
预计年份：2026年 4.1809亿美元
预测年份 2032 6.8794亿美元
复合年增长率 (%) 8.57%

对脂肪酸合成酶抑制剂计画的治疗证据、转化研究趋势和关键临床开发挑战进行了权威概述。

脂肪酸合成酶（FASN）抑制剂透过靶向脂质代谢异常（许多固体癌的特征性表现），已成为肿瘤治疗领域一个极具前景的方向。过去十年，科学界已累积了大量临床前证据，显示FASN诱导的脂质生物合成与肿瘤生长、转移和治疗抗药性密切相关。这些治疗证据推动了转化研究的蓬勃发展，旨在将代谢脆弱性转化为临床可应用的干预措施。因此，FASN抑制如今已成为精准肿瘤学、代谢生物学和联合治疗策略的交会点。

科学突破、适应性调查方法和商业性需求的融合如何重塑 FASN 抑制剂的开发策略。

FASN抑制剂的研发格局正经历着一场变革性的转变，这主要由科学、临床和商业性因素共同驱动。肿瘤代谢研究的进展揭示了FASN活性与致癌讯号通路之间的机制联繫，从而改善了标靶验证和生物标记策略。同时，临床试验设计也在不断发展，引入了适应性通讯协定、筛选患者群以及早期采用动态终点，以加快决定是否继续或终止研发的进程。这些调查方法的改进改变了研发者的风险状况，并重塑了生技公司与大型製药公司之间的伙伴关係动态。

2025 年美国关税政策调整对生技药品研发的采购、供应连续性和专案优先顺序的综合营运和策略影响。

近期对2025年贸易政策和关税结构的调整正对生物製药供应链产生累积影响，并波及到与FASN抑制剂计画相关的研究、临床开发和生产活动。某些化学品、实验室耗材和专用设备的进口关税提高，增加了活性药物成分和关键原料的直接采购成本。这些成本压力促使专案发起公司重新评估其供应商组合，协商长期合同，并在某些情况下加快对国内供应商或替代供应商的认证，以降低未来贸易中断带来的风险。

精细的细分洞察，将特定适应症的生物学、治疗方法多样性、製剂选择、终端用户趋势和管道要求与转换优先顺序相结合。

细分市场层面的趋势揭示了每种适应症、产品类型、剂型、终端用户和分销管道所面临的独特机会和挑战，因此需要製定个人化的开发和商业化策略。治疗领域包括乳癌、肝细胞癌、卵巢癌和摄护腺癌，每种适应症都有独特的分子背景、患者群体和标准治疗方案，这些都会影响临床概念验证。

决定全球主要地区监管参与程度、临床试验效率和商业化路径的区域因素和跨国商业策略。

地理因素对全球主要地区的临床开发、供应链设计、监管互动和商业化路径的影响方式各不相同。在美洲，监管合作、支付方趋势和临床试验基础设施支持快速概念验证研究和早期商业化策略，尤其註重产生能够证明显着临床效益和安全性的证据。欧洲、中东和非洲（EMEA）地区的监管环境和报销机制则较为复杂，各国决策、区域参考定价机制以及不断变化的临床试验网络，都需要量身定制的监管应对措施和市场准入策略，以最大限度地提高市场渗透率和市场接受度。

透过模式专业知识、生物标记整合和伙伴关係模式，制定竞争和企业策略，使开发商脱颖而出，并推动 FASN 抑制剂产品组合的发展。

FASN抑制剂研发领域的竞争格局呈现出两极化的特点：既有专注于早期候选药物研发的专业生物技术公司，也有透过合作、授权和内部专案探索代谢肿瘤学的大型製药企业。主要企业除了拥有专有的化学分型、抗体工程技术或胜肽设计平台外，还致力于透过整合生物标记开发和伴随诊断策略来实现策略差异化。从与学术机构合作进行标靶检验，到与成熟的肿瘤治疗公司达成共同开发契约，各种合作模式在加速临床应用和利用后期研发经验方面继续发挥核心作用。

为开发商提供切实可行的策略行动，透过协调生物标记主导的临床试验、联合治疗、弹性供应链和支付方合作，加速临床和商业性成功。

产业领导者应采取积极主动的综合策略，将科学检验、临床策略、生产韧性和商业规划相结合，以充分释放FASN标靶治疗方法的潜力。首先，应优先进行转化研究项目，纳入预测性生物标记和动态终点，以降低临床开发风险并优化患者选择。其次，应儘早设计采用成熟治疗方法的联合治疗研究，以确保在后期投资前充分了解安全性和给药顺序等因素。这些措施将增强与监管机构和支付方咨询所需的证据，从而提高获得具有临床意义的疗效的可能性。

结合文献整合、监管分析、专家访谈和营运场景评估的多方面研究框架，得出基于证据的策略见解。

本分析整合了跨学科调查方法，结合专家访谈、同行评审文献综述、监管指南审查和营运案例研究分析，以得出可操作的见解。该方法首先系统地回顾临床前和临床出版物，以确定FASN抑制的科学基础，并识别检验的生物标记、机制数据和安全性讯号。接下来，审查监管文件和指南，以阐明与临床开发相关的路径，并确定关于生物标记使用和联合治疗核准的不断变化的预期。

将科学潜力、实际情况和战略重点进行简洁整合，以将 FASN 抑制从转化成功转化为临床影响。

总之，FASN抑制剂透过标靶肿瘤脂质代谢，在肿瘤治疗领域占有重要的策略地位，为解决多种肿瘤类型的治疗抗药性和生物依赖性问题提供了机会。该领域正从机制检验转向以生物标记为导向的临床开发和可执行的商业化计划，并透过治疗方法多样化和製剂创新来拓展治疗手段。 2025年的关税调整和供应链波动带来了营运挑战，但同时也促使企业进行策略供应商多元化和生产优化，从而增强长期专案的韧性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 FASN抑制剂市场：依适应症划分

  • 乳癌
  • 肝细胞癌
  • 卵巢癌
  • 摄护腺癌

第九章 FASN抑制剂市场：依产品类型划分

  • 抗体抑制剂
  • 胜肽抑制剂
  • 低分子化合物

第十章：以剂型分類的FASN抑制剂市场

  • 注射药物
    • 肌肉内部
    • 静脉
  • 口服

第十一章 FASN抑制剂市场：依最终用户划分

  • 医院
  • 研究机构
  • 专科诊所

第十二章 FASN抑制剂市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 FASN抑制剂市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 FASN抑制剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 FASN抑制剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国FASN抑制剂市场

第十七章：中国FASN抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Abcam Limited
  • Antipodean Pharmaceuticals
  • Ascletis Pharma Inc.
  • Bio-Techne Corporation
  • Boehringer Ingelheim International GmbH
  • Cayman Chemical Company
  • Enzo Biochem, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • MedChemExpress
  • Merck KGaA
  • Niksan Pharmaceutical
  • Pfizer Inc.
  • Sagimet Biosciences
  • Santa Cruz Biotechnology, Inc.
  • Spansules Pharma
  • Takeda Pharmaceutical Company Limited
  • VWR International by Avantor
Product Code: MRR-6A132FD32B24

The FASN Inhibitor Market was valued at USD 386.87 million in 2025 and is projected to grow to USD 418.09 million in 2026, with a CAGR of 8.57%, reaching USD 687.94 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 386.87 million
Estimated Year [2026] USD 418.09 million
Forecast Year [2032] USD 687.94 million
CAGR (%) 8.57%

An authoritative orientation to the therapeutic rationale, translational momentum, and clinical development imperatives shaping fatty acid synthase inhibitor programs

Fatty acid synthase (FASN) inhibitors represent a promising therapeutic axis within oncology by targeting aberrant lipid metabolism, a hallmark of several solid tumors. Over the past decade, the scientific community has consolidated preclinical evidence that links FASN-driven lipogenesis to tumor growth, metastasis, and treatment resistance. This therapeutic rationale has catalyzed a wave of translational efforts aimed at converting metabolic vulnerabilities into clinically actionable interventions. As a result, FASN inhibition is now positioned at the intersection of precision oncology, metabolic biology, and combination therapy strategies.

Clinicians and researchers have increasingly focused on identifying predictive biomarkers and optimizing drug delivery modalities to enhance the therapeutic index of FASN-targeted agents. Concurrent advances in medicinal chemistry and biologics engineering have broadened the spectrum of product types under investigation, spanning small molecules, peptides, and antibody-based approaches. As the field advances, important considerations include patient selection algorithms, combinatorial regimens with standard-of-care therapies, and vigilant assessment of safety profiles related to systemic lipid modulation. Together, these elements shape a dynamic early-to-mid stage development environment that warrants strategic attention from developers, research institutions, and clinical stakeholders.

How converging scientific breakthroughs, adaptive clinical methodologies, and commercial imperatives are reshaping development strategies for FASN inhibitors

The landscape for FASN inhibitor development is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Advances in tumor metabolism research have clarified mechanistic links between FASN activity and oncogenic signaling, which in turn has refined target validation and biomarker strategies. At the same time, clinical trial design has evolved to incorporate adaptive protocols, enriched patient cohorts, and earlier integration of pharmacodynamic endpoints to accelerate go/no-go decisions. These methodological refinements have altered risk profiles for developers and reshaped partnership dynamics between biotechs and larger pharmaceutical sponsors.

On the technological front, improvements in formulation science and delivery systems have enabled more precise targeting and dosing flexibility, opening opportunities for both systemic and localized administration. Regulatory agencies have signaled openness to robust biomarker-driven pathways and combination study designs, prompting sponsors to align translational research with regulatory expectations earlier in development. Commercially, payers and health systems are increasingly attentive to value demonstrations that connect metabolic modulation to durable clinical benefit and real-world outcomes. Together, these shifts are redefining program priorities and elevating the importance of integrated strategies that span discovery, clinical development, manufacturing, and market access planning.

The aggregate operational and strategic consequences of adjusted United States tariff policies in 2025 on procurement, supply continuity, and program prioritization within biologics development

Recent adjustments to trade policies and tariff structures in 2025 have exerted cumulative effects on the biopharmaceutical supply chain that ripple through research, clinical development, and manufacturing activities relevant to FASN inhibitor programs. Heightened import duties on selected chemicals, laboratory consumables, and specialized equipment have increased direct procurement costs for active pharmaceutical ingredients and critical raw materials. These cost pressures have prompted sponsors to reassess supplier portfolios, negotiate longer-term contracts, and, in some cases, accelerate qualification of domestic or alternative suppliers to mitigate exposure to future trade disruptions.

Beyond direct input costs, tariff-driven supply chain friction has influenced logistics and lead times for clinical supplies and investigational medicinal products, requiring sponsors to build greater inventory buffers and contingency plans. This operational response has implications for trial timelines and budget allocations, especially for programs that rely on specialized reagents and outsourced manufacturing. Moreover, the cumulative tariff environment has encouraged more strategic sourcing decisions, including regional diversification of manufacturing and an increased emphasis on upstream vertical integration where feasible. While such adjustments can safeguard continuity, they also demand capital and managerial bandwidth, thereby influencing program prioritization and partnership structures across the FASN inhibitor ecosystem.

Nuanced segmentation insights that align indication-specific biology, modality diversity, formulation choices, end-user dynamics, and channel imperatives for translational prioritization

Segment-level dynamics reveal differentiated opportunities and constraints across indications, product types, formulations, end users, and distribution channels, each requiring tailored development and commercialization strategies. The therapeutic focus spans breast cancer, hepatocellular carcinoma, ovarian cancer, and prostate cancer, with each indication presenting distinct molecular contexts, patient populations, and standard-of-care backdrops that influence trial design and positioning. Product development pathways include antibody inhibitors, peptide inhibitors, and small molecule approaches, each with unique discovery challenges, development timelines, and regulatory considerations that affect the pathway to clinical proof-of-concept.

Formulation and route of administration considerations further shape clinical development and market access approaches: both injectable and oral formulations are under evaluation, with injectable options subdivided into intramuscular and intravenous modalities that demand specific formulation expertise and administration logistics. End users include hospitals, research institutes, and specialty clinics that differ in procurement practices, clinical trial participation, and adoption patterns. Distribution channels comprise hospital pharmacies, online pharmacies, and retail pharmacies, each presenting distinct compliance, dispensing, and reimbursement landscapes. Integrating insights across these segmentation dimensions enables sponsors to prioritize assets, tailor clinical development plans, and design commercial strategies that align with clinician workflows and patient preferences.

Regional considerations and cross-border operational strategies that determine regulatory engagement, trial execution efficiency, and commercialization pathways across major global territories

Geographic dynamics influence clinical development, supply chain design, regulatory engagement, and commercialization pathways in distinct ways across primary global regions. In the Americas, regulatory interactions, payer dynamics, and clinical trial infrastructure support rapid proof-of-concept studies and early commercialization strategies, with particular emphasis on evidence generation that demonstrates meaningful clinical benefit and safety. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where country-level decision-making, regional reference pricing mechanisms, and variable clinical trial networks necessitate tailored regulatory and market access approaches to maximize penetration and uptake.

Asia-Pacific encompasses diverse healthcare systems, growing clinical research capacity, and manufacturing hubs that can offer both rapid patient enrollment and cost-efficient production capabilities. Sponsors frequently leverage this region for late-stage trial recruitment and supply chain flexibility, while also navigating complex regulatory timelines and local clinical practice patterns. Across all regions, successful programs harmonize regulatory science, local stakeholder engagement, and operational logistics to optimize trial execution and commercialization readiness, while also recognizing regional differences in standard-of-care, diagnostic infrastructure, and payer expectations.

Competitive dynamics and corporate strategies that differentiate developers through modality expertise, biomarker integration, and partnership models to advance FASN inhibitor portfolios

The competitive landscape for FASN inhibitor development is characterized by a mix of specialized biotechs advancing early-stage candidates and larger pharmaceutical companies exploring metabolic oncology through partnerships, in-licensing, and internal programs. Key companies emphasize strategic differentiation through proprietary chemotypes, antibody engineering expertise, or peptide design platforms, as well as through integrated biomarker development and companion diagnostic strategies. Collaboration models-ranging from academic partnerships for target validation to co-development agreements with established oncology sponsors-remain central to accelerating clinical translation and accessing late-stage development expertise.

Strategic priorities among leading organizations include optimizing target engagement, minimizing off-target metabolic consequences, and designing combination regimens that complement established therapeutic modalities such as endocrine therapy, targeted agents, and immuno-oncology treatments. Additionally, companies are investing in manufacturing capabilities and formulation science to support scalable production and to offer distinct dosing modalities that meet clinical and marketplace needs. Intellectual property strategies, data exclusivity planning, and early payer engagement are also prominent considerations as firms seek to protect value and create pathways to sustainable adoption in clinical practice.

Practical strategic actions for developers that align biomarker-driven trials, combination regimens, resilient supply chains, and payer engagement to accelerate clinical and commercial success

Industry leaders should adopt a proactive, integrated approach that aligns scientific validation, clinical strategy, manufacturing resilience, and commercial planning to unlock the broader potential of FASN-directed therapies. First, prioritize translational programs that incorporate predictive biomarkers and pharmacodynamic endpoints to de-risk clinical development and improve patient selection. Second, design combination studies with established therapeutic regimens early, ensuring that safety and sequencing considerations are understood before late-stage investment. These steps will enhance the evidence package required for regulatory and payer discussions and increase the probability of clinically meaningful outcomes.

Operationally, diversify supplier networks and qualify alternative manufacturing partners to mitigate potential supply chain and tariff-related disruptions. Invest in formulation strategies that enable both oral and injectable dosing where scientifically justified to maximize clinical applicability and patient convenience. From a commercial perspective, engage payers and key clinical opinion leaders early to define value frameworks and real-world evidence needs. Finally, pursue flexible collaboration models that allow smaller innovators to leverage the development horsepower of larger organizations while preserving upside through smart deal structures and milestone-based partnerships.

A multi-method research framework combining literature synthesis, regulatory analysis, expert consultation, and operational scenario assessment to produce evidence-based strategic insights

This analysis integrates a cross-disciplinary research methodology that combines expert interviews, peer-reviewed literature synthesis, regulatory guidance review, and operational case study analysis to produce actionable insights. The approach begins with a systematic review of preclinical and clinical publications to establish the scientific underpinning of FASN inhibition and to identify validated biomarkers, mechanistic data, and safety signals. Next, regulatory documents and guidance were examined to map relevant pathways for clinical development and to identify evolving expectations around biomarker use and combination therapy approvals.

Complementing the literature-based approach, the methodology includes structured consultations with clinical investigators, formulation scientists, regulatory strategists, and manufacturing specialists to ground findings in operational realities. Supply chain assessments evaluated sourcing risk, potential tariff implications, and mitigation strategies through scenario-based analysis. Finally, competitive and commercial insights were derived from product development disclosures, partnership announcements, and public corporate filings to identify strategic trajectories and common success factors. This triangulated methodology ensures the findings are both evidence-based and practical for decision-makers.

A concise synthesis of scientific promise, operational realities, and strategic priorities required to translate FASN inhibition from translational success to clinical impact

In sum, FASN inhibitors occupy a strategically important niche in oncology by targeting tumor lipid metabolism, offering opportunities to address treatment resistance and biological dependencies across multiple tumor types. The field is transitioning from mechanistic validation toward biomarker-enabled clinical development and pragmatic commercial planning, with modality diversity and formulation innovation expanding the therapeutic toolkit. While tariff adjustments and supply chain dynamics in 2025 have introduced operational challenges, they have also sparked strategic supplier diversification and manufacturing optimization that can strengthen long-term program resilience.

Moving forward, successful programs will integrate translational rigor, adaptive clinical design, and supply chain foresight, while engaging regulatory and payer stakeholders early to clarify evidence requirements. Collaboration across academia, industry, and clinical networks will remain essential to validate combinations and identify patient cohorts most likely to benefit. With disciplined execution and a focus on value demonstration, developers can translate preclinical promise into therapies that deliver meaningful outcomes for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. FASN Inhibitor Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Hepatocellular Carcinoma
  • 8.3. Ovarian Cancer
  • 8.4. Prostate Cancer

9. FASN Inhibitor Market, by Product Type

  • 9.1. Antibody Inhibitor
  • 9.2. Peptide Inhibitor
  • 9.3. Small Molecule

10. FASN Inhibitor Market, by Formulation

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
  • 10.2. Oral

11. FASN Inhibitor Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. FASN Inhibitor Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. FASN Inhibitor Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. FASN Inhibitor Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. FASN Inhibitor Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States FASN Inhibitor Market

17. China FASN Inhibitor Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abcam Limited
  • 18.7. Antipodean Pharmaceuticals
  • 18.8. Ascletis Pharma Inc.
  • 18.9. Bio-Techne Corporation
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Cayman Chemical Company
  • 18.12. Enzo Biochem, Inc.
  • 18.13. Gilead Sciences, Inc.
  • 18.14. GlaxoSmithKline PLC
  • 18.15. Johnson & Johnson Services, Inc.
  • 18.16. Manus Aktteva Biopharma LLP
  • 18.17. MedChemExpress
  • 18.18. Merck KGaA
  • 18.19. Niksan Pharmaceutical
  • 18.20. Pfizer Inc.
  • 18.21. Sagimet Biosciences
  • 18.22. Santa Cruz Biotechnology, Inc.
  • 18.23. Spansules Pharma
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. VWR International by Avantor

LIST OF FIGURES

  • FIGURE 1. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FASN INHIBITOR MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FASN INHIBITOR MARKET SIZE, BY ANTIBODY INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FASN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FASN INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FASN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FASN INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FASN INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS FASN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FASN INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. NATO FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA FASN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA FASN INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA FASN INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA FASN INHIBITOR MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA FASN INHIBITOR MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA FASN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA FASN INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)